Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
STRATEC Biomedical AG (GB:0RAR)
LSE:0RAR
RESEARCH TOOLSreports
Holding GB:0RAR?
Track your performance easily
0RAR Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€26.35 - €48.55
Previous Close€27.7
Volume1.88K
Average Volume (3M)7.07K
Market Cap
€336.72M
Enterprise Value€399.80M
Total Cash (Recent Filing)€24.07M
Total Debt (Recent Filing)€87.15M
Price to Earnings (P/E)33.6
Beta0.67
Next Earnings
Mar 26, 2025EPS EstimateN/A
Last Dividend Ex-Date
May 20, 2024Dividend Yield1.97%
Share Statistics
EPS (TTM)0.82
Shares OutstandingN/A
10 Day Avg. Volume65
30 Day Avg. Volume7,072
Standard Deviation0.10
R-Squared0.00013
Alpha-0.00519
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)2.74
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€40.20Price Target Upside45.13% Upside
Rating ConsensusHold
Number of Analyst Covering5
STRATEC Biomedical News
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
11.92% Mutual Funds
― Other Institutional Investors
85.96% Public Companies and
Individual Investors
0RAR FAQ
What was STRATEC Biomedical AG’s price range in the past 12 months?
STRATEC Biomedical AG lowest share price was €26.35 and its highest was €48.55 in the past 12 months.
What is STRATEC Biomedical AG’s market cap?
Currently, no data Available
When is STRATEC Biomedical AG’s upcoming earnings report date?
STRATEC Biomedical AG’s upcoming earnings report date is Mar 26, 2025 which is in 119 days.
How were STRATEC Biomedical AG’s earnings last quarter?
STRATEC Biomedical AG released its earnings results on Oct 25, 2024. The company reported €0.05 earnings per share for the quarter, missing the consensus estimate of €0.38 by -€0.33.
Is STRATEC Biomedical AG overvalued?
According to Wall Street analysts STRATEC Biomedical AG’s price is currently Undervalued.
Does STRATEC Biomedical AG pay dividends?
STRATEC Biomedical AG pays a Annually dividend of €0.55 which represents an annual dividend yield of 1.97%. See more information on STRATEC Biomedical AG dividends here
What is STRATEC Biomedical AG’s EPS estimate?
STRATEC Biomedical AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does STRATEC Biomedical AG have?
STRATEC Biomedical AG has 12,157,841 shares outstanding.
What happened to STRATEC Biomedical AG’s price movement after its last earnings report?
STRATEC Biomedical AG reported an EPS of €0.05 in its last earnings report, missing expectations of €0.38. Following the earnings report the stock price went down -0.986%.
Which hedge fund is a major shareholder of STRATEC Biomedical AG?
Currently, no hedge funds are holding shares in GB:0RAR
---
STRATEC Biomedical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.91%
12-Months-Change
Fundamentals
Return on Equity
4.41%
Trailing 12-Months
Asset Growth
1.75%
Trailing 12-Months
Company Description
STRATEC Biomedical AG
Stratec SE designs and manufactures automated analyzer systems for laboratory data management and solutions for molecular diagnostic sample preparation and stabilization. Its business segments are Instrumentation, Diatron, Smart Consumables, and Others. The company generates maximum revenue from the Instrumentation segment. Its Instrumentation segment is engaged in designing and manufacturing automated analyzer systems for the clinical diagnostics and biotechnology customers. The Diatron segment comprises the business with systems, system components, consumables and tests in the low throughput hematology and clinical chemistry segment. Its Smart Consumables segment is engaged in developing and selling scientific materials, such as nucleic acid purification.
---
0RAR Stock 12 Month Forecast
Average Price Target
€40.20
▲(45.13% Upside)
Technical Analysis
Best Analysts Covering 0RAR
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-30.20%
reiterated a buy rating last month
Copying Odysseas Manesiotis's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -30.20% per trade.
---